^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Trazimera (trastuzumab-qyyp) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
07/26/2018
Excerpt:
Trazimera is indicated for the treatment of...Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments….Trazimera should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.
Source:
Published date:
07/26/2018
Excerpt:
Trazimera is indicated for the treatment of...in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab....Trazimera should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.
Secondary therapy:
Aromatase inhibitor
Source:
Title:
Neoadjuvant therapy with Pembrolizumab in combination with anti-HER2-blockade with trastuzumab and pertuzumab in early breast cancer patients with HER2+ and hormonal receptor positive or negative early breast cancer. Neoadjuvante Therapie mit Pembrolizumab in Kombination mit einer anti-HER2 Blockade mit Trastuzumab und Pertuzumab bei Patientinnen im Frühstadium von Brustkrebs mit HER+ und Hormonrezeptor positiven oder negativen Brustkrebs.
Excerpt:
...Confirmed HER2neu [IHC 2+ status and amplification (e.g. FISH)] or [IHC 3+ status] tumor identification by local pathology. ...
Trial ID:
